Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.
2001
122
LTM Revenue $11.9M
LTM EBITDA -$18.2M
$74.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of August 2025, Pacific Edge reported last 12-month revenue of $11.9M and EBITDA of -$18.2M.
In the same period, Pacific Edge generated $4.6M in LTM gross profit and -$18.9M in net income.
See Pacific Edge valuation multiples based on analyst estimatesIn the most recent fiscal year, Pacific Edge reported revenue of $12.9M and EBITDA of -$18.7M.
Pacific Edge expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Pacific Edge valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $11.9M | XXX | $12.9M | XXX | XXX | XXX |
Gross Profit | $4.6M | XXX | $12.9M | XXX | XXX | XXX |
Gross Margin | 38% | XXX | 100% | XXX | XXX | XXX |
EBITDA | -$18.2M | XXX | -$18.7M | XXX | XXX | XXX |
EBITDA Margin | -152% | XXX | -145% | XXX | XXX | XXX |
EBIT | -$19.9M | XXX | -$20.1M | XXX | XXX | XXX |
EBIT Margin | -167% | XXX | -156% | XXX | XXX | XXX |
Net Profit | -$18.9M | XXX | -$17.6M | XXX | XXX | XXX |
Net Margin | -158% | XXX | -137% | XXX | XXX | XXX |
Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pacific Edge has current market cap of NZD 145M (or $85.6M), and EV of NZD 126M (or $74.0M).
As of September 19, 2025, Pacific Edge's stock price is NZD 0 (or $0).
See Pacific Edge trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$74.0M | $85.6M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialPacific Edge's trades at 5.6x EV/Revenue multiple, and -3.9x EV/EBITDA.
See valuation multiples for Pacific Edge and 15K+ public compsAs of September 19, 2025, Pacific Edge has market cap of $85.6M and EV of $74.0M.
Equity research analysts estimate Pacific Edge's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pacific Edge has a P/E ratio of -4.5x.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $85.6M | XXX | $85.6M | XXX | XXX | XXX |
EV (current) | $74.0M | XXX | $74.0M | XXX | XXX | XXX |
EV/Revenue | 6.2x | XXX | 5.6x | XXX | XXX | XXX |
EV/EBITDA | -4.1x | XXX | -3.9x | XXX | XXX | XXX |
EV/EBIT | -3.7x | XXX | -3.6x | XXX | XXX | XXX |
EV/Gross Profit | 16.2x | XXX | n/a | XXX | XXX | XXX |
P/E | -4.5x | XXX | -4.9x | XXX | XXX | XXX |
EV/FCF | -5.0x | XXX | -4.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPacific Edge's last 12 month revenue growth is 37%
Pacific Edge's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Pacific Edge's rule of 40 is -108% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacific Edge's rule of X is -61% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pacific Edge and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 37% | XXX | 22% | XXX | XXX | XXX |
EBITDA Margin | -152% | XXX | -145% | XXX | XXX | XXX |
EBITDA Growth | -16% | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | -108% | XXX | -108% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | -61% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 80% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 67% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 256% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacific Edge acquired XXX companies to date.
Last acquisition by Pacific Edge was XXXXXXXX, XXXXX XXXXX XXXXXX . Pacific Edge acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Pacific Edge founded? | Pacific Edge was founded in 2001. |
Where is Pacific Edge headquartered? | Pacific Edge is headquartered in New Zealand. |
How many employees does Pacific Edge have? | As of today, Pacific Edge has 122 employees. |
Is Pacific Edge publicy listed? | Yes, Pacific Edge is a public company listed on NZE. |
What is the stock symbol of Pacific Edge? | Pacific Edge trades under PEB ticker. |
When did Pacific Edge go public? | Pacific Edge went public in 2003. |
Who are competitors of Pacific Edge? | Similar companies to Pacific Edge include e.g. AnteoTech, Proteomics International, Biohit, Genomictree. |
What is the current market cap of Pacific Edge? | Pacific Edge's current market cap is $85.6M |
What is the current revenue of Pacific Edge? | Pacific Edge's last 12 months revenue is $11.9M. |
What is the current revenue growth of Pacific Edge? | Pacific Edge revenue growth (NTM/LTM) is 37%. |
What is the current EV/Revenue multiple of Pacific Edge? | Current revenue multiple of Pacific Edge is 6.2x. |
Is Pacific Edge profitable? | Yes, Pacific Edge is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Pacific Edge? | Pacific Edge's last 12 months EBITDA is -$18.2M. |
What is Pacific Edge's EBITDA margin? | Pacific Edge's last 12 months EBITDA margin is -152%. |
What is the current EV/EBITDA multiple of Pacific Edge? | Current EBITDA multiple of Pacific Edge is -4.1x. |
What is the current FCF of Pacific Edge? | Pacific Edge's last 12 months FCF is -$14.7M. |
What is Pacific Edge's FCF margin? | Pacific Edge's last 12 months FCF margin is -123%. |
What is the current EV/FCF multiple of Pacific Edge? | Current FCF multiple of Pacific Edge is -5.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.